[1] [1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. A Cancer Journal for Clinicians, 2018, 68(6): 394-424.

[2] [2] LI A, ZHANG Y, WANG Z, et al. The roles and signaling pathways of prolyl-4-hydroxylase 2 in the tumor microenvironment［J］. Chemico-biological Interactions, 2019, 303: 40-49.

[3] [3] DI C G, TRUSSO C S, LOROCH S, et al. The mTOR and PP2A pathways regulate PHD2 phosphorylation to fine-tune HIF1α levels and colorectal cancer cell survival under hypoxia［J］. Cell Reports, 2017, 18(7): 1699-1712.

[4] [4] KATO H, INOUE T, ASANOMA K, et al. Induction of human endometrial cancer cell senescence through modulation of HIF-1α activity by EGLN1［J］. International Journal of Cancer, 2006, 118(5): 1144-1153.

[5] [5] BRIGGS K J, KOIVUNEN P, CAO S, et al. Paracrine induction of HIF by glutamate in breast cancer: EglN1 senses cysteine［J］. Cell, 2016, 166(1): 126-139.

[6] [6] LANIKOVA L, READING N S, HU H, et al. Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer［J］. Oncotarget, 2017, 8(7): 11739-11747.

[7] [7] MERING C, HUYNEN M, JAEGGI D. STRING: a database of predicted functional associations between proteins［J］. Nucleic Acids Research, 2003, 31(1): 258-261.

[8] [8] HASUMI H, YAO M. Hereditary kidney cancer syndromes: genetic disorders driven by alterations in metabolism and epigenome regulation［J］. Cancer Science, 2018, 109(3): 581-586.

[9] [9] STONE L. Kidney cancer: activation of oncogenes driven by VHL loss in ccRCC［J］. Nature Reviews Urology, 2017, 14(11): 637.

[10] [10] HUANG Y, LIN D, TANIGUCHI C M. Hypoxia-inducible factor (HIF) in human tumorigenesis［J］. Science China Life Sciences, 2017, 60(10): 1114-1124.

[11] [11] FANG Y, BAO W, RAO Q, et al. TFE3 regulates renal adenocarcinoma cell proliferation via activation of the mTOR pathway［J］. Molecular Medicine Reports, 2017, 16(3): 2721-2725.

[12] [12] CAO Q, JU X, LI P, et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk［J］. PLoS One, 2012, 7(11): e50302.

[13] [13] COOMANS D, DEMOULIN J B. FOXO transcription factors in cancer development and therapy［J］. Cellular and Molecular Life Sciences, 2016, 73(6): 1159-1172.

[14] [14] NIE W, NI D, MA X, et al. MiR-122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing forkhead box O3［J］. International Journal of Oncology, 2019, 54(2): 559-571.

[15] [15] KAELIN W, RATCLIFFE P. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway［J］. Molecular Cell, 2008, 30(4): 393-402.

[16] [16] JIANG L, SHI S, SHI Q, et al. Similarity in the functions of HIF-1α and HIF-2α proteins in cervical cancer cells［J］. Oncology Letters, 2017, 14(5): 5643-5651.

[18] [18] KOZLOVA N, WOTTAWA M, KATSCHINSKI D, et al. Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer［J］. Oncotarget, 2017, 8(6): 9885-9898.

[19] [19] ZHEN L, SHIJIE N, SHUIJUN Z, et al. Tumor PHD2 expression is correlated with clinical features and prognosis of patients with HCC receiving liver resection［J］. Medicine (Baltimore), 2014, 93(29): e179.

[20] [20] XU X L, GONG Y, ZHAO D P. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma［J］. European Review For Medical And Pharmacological Sciences, 2018, 22(24): 8731-8739.

[22] [22] CHIRS D M, JESPER T P, FREJA A V, et al. Hypoxia and loss of PHD 2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis［J］. EMBO Reports, 2015, 16(10): 1394-1408.

[23] [23] LIU S, ZHANG G, GUO J, et al. Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis［J］. Nature Communications, 2018, 9(1): 5426.